# US 5,858,345 A · In vivo polymerizable ophthalmic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,345 A
- Document ID: US5858345A
- Status: Granted
- Kind: A
- Application number: 08/833,635
- Filed: 1997-04-08
- Granted: 1999-01-12
- Earliest claimed: 1997-04-08
- Assignees: Alcon Laboratories, Inc.; Univ. of Southern Mississippi
- Inventors: Steven T. Charles; Mark E. Hammer; John C. Lang; Robert Y. Lochhead; Lon J. Mathias
- Web page: https://patentgrep.com/patent/US5858345A

## CPC

- C08F 20/22: Esters containing halogen
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/25: with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
- A61K 31/78: of acrylic acid or derivatives thereof
- A61K 31/785: Polymers containing nitrogen
- C08F 20/04: Acids, Metal salts or ammonium salts thereof
- C08F 22/1006: {of polyhydric alcohols or polyhydric phenols, e.g. ethylene glycol dimethacrylate}
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Ophthalmic compositions containing biocompatible, bioadhesive polymerizable amphipathic mesophase materials useful for repairing retinal tissue tears or retinal detachments are disclosed. In one embodiment, the polymerizable materials, which comprise substituted fluoroalkyl or perfluoroalkyl monomers having anionic, cationic, and/or nonionic surface active functionality in the unsaturated fluorophobic ends, are polymerized in vivo to provide effective, long-lasting repair of torn, ruptured or detached retinal tissue. Ophthalmic applications of these materials are not limited to retinal repair.

## Claims

### Claim 1

An ophthalmic composition comprising an ophthalmically acceptable vehicle and a biocompatible, in vivo polymerizable monomer of the structure ##STR7## wherein n is 2-20;
w is 1-20;
q is 0, 1;
Y is H, F;
T is --CH.dbd.CH--, --CH.sub.2 --C(.dbd.CH.sub.2)--;
R is OH, OH.sup.- M.sup.+, OCH.sub.3, NH(CH.sub.2).sub.n N(CH.sub.3).sub.3.sup.+ X.sup.-, (OCH.sub.2 CH.sub.2).sub.w N(CH.sub.3).sub.3.sup.+ X.sup.-, OCH.sub.2 C(CH.sub.2 OH).sub.3, ##STR8## R' is H, CH.sub.3 CH.sub.2 CO.sub.2 H, CH.sub.2 COO.sup.- M.sup.+ ; m is 1-100;
M.sup.+ is a pharmaceutically acceptable cation; and
X.sup.- is a pharmaceutically acceptable anion.

### Claim 2 (depends on 1)

The ophthalmic composition of claim 1 further comprising a compound selected from the group consisting of ##STR9## wherein: P, Q, and R are independently H, CH.sub.3 ;
a and b are independently 1-100;
II) YCF.sub.2 (CF.sub.2).sub.c (CH.sub.2).sub.d O(C(T)HCH.sub.2 O).sub.e (CH.sub.2).sub.d (CF.sub.2).sub.c CF.sub.2 Y
wherein:
T is H, CH.sub.3 ;
Y is H, F;
c is 1-20;
d is 1-4;
e is 1-100; and ##STR10## wherein n is 2-20;
m is 1-100;
Y is H, F; and
P and Q are independently H, CH.sub.3.

### Claim 3 (depends on 1)

The ophthalmic composition of claim 1 wherein the total concentration of the monomer of structure I is from about 1 to about 60 wt. %.

### Claim 4 (depends on 3)

The ophthalmic composition of claim 3 wherein the total concentration of the monomer of structure I is from about 10 to about 35 wt. %.

### Claim 5 (depends on 1)

The ophthalmic composition of claim 1 wherein the composition comprises about 30 wt. % of 2-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8)-pentadecafluorooctyl-oxy-methyl!-2-prop enoic acid and has a pH of about 7.3-7.5.

### Claim 6 (depends on 1)

The ophthalmic composition of claim 1 wherein the composition comprises 40 wt. % water, 50 wt. % of the compound of the structure ##STR11## and 10 wt. % of the compound of the structure ##STR12##

### Claim 7 (depends on 6)

The ophthalmic composition of claim 6 further comprising the compound of the structure ##STR13## and the compound of the structure ##STR14##

### Claim 8 (depends on 1)

The ophthalmic composition of claim 1 wherein the composition comprises 40 wt. % water, 53 wt. % of the compound of the structure ##STR15## and 7 wt. % of the compound of the structure ##STR16##

### Claim 9 (depends on 1)

The ophthalmic composition of claim 1 wherein the composition comprises 40 wt. % water, 53 wt. % of the compound of the structure ##STR17## and 7 wt. % of the compound of the structure ##STR18##

### Claim 10 (depends on 1)

The ophthalmic composition of claim 1 wherein the composition comprises 40 wt. % water, 28 wt. % of the compound of the structure ##STR19## and 7 wt. % of the compound of the structure ##STR20## and 25% of the compound of the structure ##STR21##

### Claim 11 (depends on 1)

A method of repairing torn or detached retinal tissue comprising administering to the site in need of repair the ophthalmic composition of claim 1, and then polymerizing the composition in vivo.

### Claim 12 (depends on 11)

The method of claim 11 wherein the in vivo polymerization is initiated by ambient light.

### Claim 13 (depends on 11)

The method of claim 11 wherein the in vivo polymerization is initiated by a redox system.

### Claim 14 (depends on 13)

The method of claim 13 wherein the in vivo polymerization is initiated by a persulfate selected from the group consisting of ammonium persulfate and potassium persulfate.

### Claim 15 (depends on 14)

The method of claim 14 wherein the in vivo polymerization is accelerated with tetramethylethylethylenediamine.
